Vladimír Koucký, Michaela Jirkovská, Aleš Vlasák, Lenka Kinštová, Jan Lazák, Eduard Zveřina, Jan Betka, Bořivoj Petrák, Pavel Tesner, Emilie Vyhnálková, Zdeněk Fík
{"title":"Efficacy of first line of bevacizumab in patients with neurofibromatosis 2-related vestibular schwannomas.","authors":"Vladimír Koucký, Michaela Jirkovská, Aleš Vlasák, Lenka Kinštová, Jan Lazák, Eduard Zveřina, Jan Betka, Bořivoj Petrák, Pavel Tesner, Emilie Vyhnálková, Zdeněk Fík","doi":"10.1007/s00405-025-09734-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>NF2-related schwannomatosis (NF2) patients are predisposed to develop multiple peripheral and central nervous tumors including bilateral vestibular schwannomas (VS). Decision on patient management, especially in large growing tumors, might be challenging concerning possible treatment-related complications and quality of life. Systemic therapy with bevacizumab has been reported to slow VS growth and improve hearing. Here, we present single-center outcomes of NF2 patients treated with bevacizumab.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 15 NF2 patients with morphologically diagnosed unilateral or bilateral VS indicated for systemic therapy with bevacizumab (5 mg/kg every 2 weeks) in 2015-2022. Tumor growth rate, volume, and hearing thresholds were assessed before, during, and after first-line bevacizumab therapy.</p><p><strong>Results: </strong>15 patients (5 male, 10 females, mean age at the start of the therapy 30y, mean no. of bevacizumab cycles 35) and 25 tumors were evaluated. Radiologically significant (> 20% from the baseline) tumor volume reduction was observed in 5 patients. Notably, in patients with bilateral VS, volume reduction occurred on only one side. Three patients demonstrated a significantly reduced growth rate and tumor stabilization. Hearing improvement was documented in 1 patient, while another experienced significant hearing decline.</p><p><strong>Conclusion: </strong>Bevacizumab therapy may contribute to tumor shrinkage and hearing stabilization in NF2 patients. However, treatment response is variable, with meaningful tumor reduction and hearing improvement observed only in a minority of cases.</p>","PeriodicalId":520614,"journal":{"name":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00405-025-09734-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: NF2-related schwannomatosis (NF2) patients are predisposed to develop multiple peripheral and central nervous tumors including bilateral vestibular schwannomas (VS). Decision on patient management, especially in large growing tumors, might be challenging concerning possible treatment-related complications and quality of life. Systemic therapy with bevacizumab has been reported to slow VS growth and improve hearing. Here, we present single-center outcomes of NF2 patients treated with bevacizumab.
Methods: We conducted a retrospective analysis of 15 NF2 patients with morphologically diagnosed unilateral or bilateral VS indicated for systemic therapy with bevacizumab (5 mg/kg every 2 weeks) in 2015-2022. Tumor growth rate, volume, and hearing thresholds were assessed before, during, and after first-line bevacizumab therapy.
Results: 15 patients (5 male, 10 females, mean age at the start of the therapy 30y, mean no. of bevacizumab cycles 35) and 25 tumors were evaluated. Radiologically significant (> 20% from the baseline) tumor volume reduction was observed in 5 patients. Notably, in patients with bilateral VS, volume reduction occurred on only one side. Three patients demonstrated a significantly reduced growth rate and tumor stabilization. Hearing improvement was documented in 1 patient, while another experienced significant hearing decline.
Conclusion: Bevacizumab therapy may contribute to tumor shrinkage and hearing stabilization in NF2 patients. However, treatment response is variable, with meaningful tumor reduction and hearing improvement observed only in a minority of cases.